OHSS
MCID: OVR029
MIFTS: 63

Ovarian Hyperstimulation Syndrome (OHSS)

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

MalaCards integrated aliases for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 57 12 58 72 36 29 13 54 6 44 15 39 70
Ohss 57 58 72
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous 57
Secondary Meig's Syndrome 12

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant

Miscellaneous:
symptoms occur only during pregnancy (usual onset after 6 weeks gestation)
major fluid shifts may occur in severe cases


HPO:

31
ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:5425
OMIM® 57 608115
KEGG 36 H01039
MeSH 44 D016471
SNOMED-CT 67 129635004
MESH via Orphanet 45 D016471
ICD10 via Orphanet 33 N98.1
UMLS via Orphanet 71 C0085083
Orphanet 58 ORPHA64739
MedGen 41 C0085083
UMLS 70 C0085083

Summaries for Ovarian Hyperstimulation Syndrome

KEGG : 36 Ovarian hyperstimulation syndrome (OHSS) is typically an iatrogenic complication of ovulation induction (OI) occurring during the luteal phase or early pregnancy. OHSS is characterised by a cystic enlargement of the ovaries and an acute fluid shift from the intravascular to the third space, which may result in ascites, pleural infusions, pericardial infusion, and even generalized edema. Majority of OHSS cases have been associated with the use of gonadotrophins for OI in anovulatory women or for ovarian stimulation (OS) in the context of assisted reproductive technology (ART). Recurrent cases and familial occurrence of OHSS have been described, and different mutations in the follicle-stimulating hormone receptor (FSHr) have been reported in these cases. Polycystic ovarian syndrome (PCOS) appears to be the major predisposing factor for OHSS in a large number of studies.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to ectopic pregnancy and pericardial effusion, and has symptoms including vomiting, abdominal pain and nausea. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and cAMP signaling pathway. The drugs Cetrorelix and Ganirelix have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are ascites and increased circulating gonadotropin level

Disease Ontology : 12 An ovarian disease that is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space and has symptom abdominal pain, has symptom nausea and has symptom vomiting. This disease is an iatrogenic complication of assisted reproduction technology.

UniProtKB/Swiss-Prot : 72 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

Wikipedia : 73 Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take... more...

More information from OMIM: 608115

Related Diseases for Ovarian Hyperstimulation Syndrome

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 ectopic pregnancy 31.2 VEGFA GNRH1 CGB5 CGA
2 pericardial effusion 30.9 VEGFA REN IL6 ALB
3 ovarian cyst 30.9 VEGFA GNRH1 CYP19A1 AMH
4 respiratory failure 30.5 VEGFA REN IL6 ALB
5 endometriosis 30.4 VEGFA KDR IL6 GNRH1 CYP19A1
6 retinal artery occlusion 30.3 VEGFA KDR IL6 F5
7 eclampsia 30.3 VEGFA REN ALB
8 central retinal vein occlusion 30.3 VEGFA IL6 F5
9 limb ischemia 30.3 VEGFA KDR IL6
10 severe pre-eclampsia 30.3 VEGFA F5 ALB
11 retinal vein occlusion 30.1 VEGFA KDR IL6 F5
12 precocious puberty 30.1 LHCGR GNRH1 FSHR CYP19A1
13 iga glomerulonephritis 30.1 REN IL6 ALB
14 cellulitis 30.0 INS IL6 ALB
15 endometriosis of ovary 30.0 GNRH1 CYP19A1 AMH
16 proteasome-associated autoinflammatory syndrome 1 30.0 INS IL6 ALB
17 choriocarcinoma 29.9 CYP19A1 CYP11A1 CGB5 CGA
18 hyperprolactinemia 29.9 SHBG INS GNRH1
19 estrogen excess 29.9 SHBG GNRH1 FSHR CYP19A1
20 hypothyroidism 29.8 SHBG REN INS GNRH1 FSHR CGA
21 hydronephrosis 29.8 VEGFA REN IL6 CYP19A1 ALB
22 proteinuria, chronic benign 29.8 VEGFA REN INS ALB
23 luteoma 29.7 SHBG FSHR CYP19A1 CGA
24 graves disease 1 29.6 SHBG INS ALB
25 type 1 diabetes mellitus 29.6 VEGFA REN INS IL6 ALB
26 polycystic ovary syndrome 29.5 SHBG INS GNRH1 FSHR CYP19A1 CYP11A1
27 chronic kidney disease 29.5 VEGFA REN INS IL6 ALB
28 liver cirrhosis 29.5 VEGFA REN INS IL6 ALB
29 hyperthyroidism 29.4 SHBG INS CGA ALB
30 hypogonadism 29.4 SHBG LHCGR INS GNRH1 FSHB
31 vascular disease 29.4 VEGFA REN INS IL6 F5 ALB
32 pre-eclampsia 29.3 VEGFA REN KDR INS IL6 F5
33 placenta disease 29.2 VEGFA REN INS IL6 F5 CGB5
34 hyperandrogenism 29.1 SHBG INS GNRH1 CYP19A1 CYP11A1
35 amenorrhea 28.8 SHBG LHCGR INS GNRH1 FSHR FSHB
36 hypogonadotropic hypogonadism 28.4 SHBG LHCGR INS GNRH1 FSHB CYP19A1
37 myocardial infarction 28.4 VEGFA SHBG REN KDR INS IL6
38 anovulation 28.4 SHBG INS GNRH1 FSHR FSHB CYP19A1
39 infertility 28.3 SHBG LHCGR INS GNRH1 FSHR FSHB
40 ovarian disease 27.6 VEGFA SHBG REN LHCGR INS IL6
41 capillary leak syndrome 11.2
42 thrombosis 10.6
43 adult respiratory distress syndrome 10.6
44 adenoma 10.6
45 thrombophilia 10.5
46 hemopericardium 10.5
47 pituitary adenoma 10.5
48 thrombophilia due to thrombin defect 10.4
49 compartment syndrome 10.4
50 mucinous cystadenofibroma 10.4 LHCGR FSHR

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:



Diseases related to Ovarian Hyperstimulation Syndrome

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 58 31 hallmark (90%) Very frequent (99-80%) HP:0001541
2 increased circulating gonadotropin level 58 31 hallmark (90%) Very frequent (99-80%) HP:0000837
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
4 enlarged polycystic ovaries 58 31 hallmark (90%) Very frequent (99-80%) HP:0008675
5 hirsutism 58 31 hallmark (90%) Very frequent (99-80%) HP:0001007
6 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
7 increased serum testosterone level 58 31 hallmark (90%) Very frequent (99-80%) HP:0030088
8 nausea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002018
9 capillary leak 58 31 hallmark (90%) Very frequent (99-80%) HP:0030005
10 pleural effusion 58 31 frequent (33%) Frequent (79-30%) HP:0002202
11 hemorrhagic ovarian cyst 58 31 frequent (33%) Frequent (79-30%) HP:0012886
12 peripheral edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0012398
13 hypovolemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011106
14 pulmonary edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100598
15 generalized edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0007430
16 nausea and vomiting 58 Very frequent (99-80%)
17 abnormality of the genitourinary system 31 HP:0000119
18 ovarian cyst 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Abdomen:
ascites
abdominal pain

Genitourinary Internal Genitalia Female:
enlarged multilocular ovaries
pathology shows multiple serous and hemorrhagic follicular cysts lined by luteinized cells ('hyperreactio luteinalis')
ovaries return to normal size after delivery

Abdomen Gastrointestinal:
nausea

Clinical features from OMIM®:

608115 (Updated 05-Apr-2021)

Symptoms:

12
  • vomiting
  • abdominal pain
  • nausea

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:


abdominal pain; nausea

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ALB AMH CGA CYP11A1 CYP19A1 F5
2 endocrine/exocrine gland MP:0005379 10.29 ALB AMH BMP15 CGA CYP11A1 CYP19A1
3 cardiovascular system MP:0005385 10.25 ALB CYP11A1 CYP19A1 F5 FSHR IL6
4 growth/size/body region MP:0005378 10.23 CGA CYP11A1 CYP19A1 F5 FSHR GNRH1
5 immune system MP:0005387 10.14 ALB CYP11A1 CYP19A1 FSHR GNRH1 IL6
6 liver/biliary system MP:0005370 10.07 ALB CYP11A1 CYP19A1 F5 GNRH1 IL6
7 digestive/alimentary MP:0005381 10.04 ALB CYP19A1 GNRH1 IL6 INS LHCGR
8 nervous system MP:0003631 10.03 CGA CYP11A1 CYP19A1 F5 FSHR GNRH1
9 muscle MP:0005369 9.92 ALB CYP11A1 CYP19A1 IL6 INS KDR
10 normal MP:0002873 9.76 ALB CYP11A1 CYP19A1 GNRH1 INS KDR
11 renal/urinary system MP:0005367 9.56 ALB CYP19A1 GNRH1 IL6 INS LHCGR
12 reproductive system MP:0005389 9.44 AMH BMP15 CGA CYP11A1 CYP19A1 FSHB

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
2
Ganirelix Approved Phase 4 124904-93-4, 123246-29-7 25081094
3
Menotropins Approved Phase 4 9002-68-0, 61489-71-2 5360545
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
6
Buserelin Approved, Investigational Phase 4 57982-77-1
7
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
8
Polyestradiol phosphate Approved Phase 4 28014-46-2
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
11
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
13 Vitamins Phase 4
14 Prolactin Release-Inhibiting Factors Phase 4
15 Chorionic Gonadotropin Phase 4
16 Hormones Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Analgesics Phase 4
20 Fibrinolytic Agents Phase 4
21 Antirheumatic Agents Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Antipyretics Phase 4
25 Platelet Aggregation Inhibitors Phase 4
26 Aromatase Inhibitors Phase 4
27 Hormone Antagonists Phase 4
28 Progestins Phase 4
29 Estradiol 3-benzoate Phase 4
30 Estradiol 17 beta-cypionate Phase 4
31 Estrogens Phase 4
32 Estrogen Receptor Antagonists Phase 4
33 Estrogen Antagonists Phase 4
34 11-hydroxyprogesterone Phase 4
35 17 alpha-Hydroxyprogesterone Caproate Phase 4
36 Caproate Phase 4
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
40
Cabergoline Approved Phase 3 81409-90-7 54746
41
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
42
Polygeline Experimental Phase 3 66455-30-9
43
Resveratrol Investigational Phase 3 501-36-0 445154
44 Plasma Substitutes Phase 3
45 Blood Substitutes Phase 3
46 Dopamine Agents Phase 3
47 Neurotransmitter Agents Phase 3
48 Dopamine agonists Phase 3
49 Antiparkinson Agents Phase 3
50 Follicle Stimulating Hormone Phase 3

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Preventive Application of GnRH Antagonist on Early Ovarian Hyperstimulation Syndrome in High-risk Women: A Prospective Randomized Trial Unknown status NCT03188471 Phase 4 GnRH antagonist;aspirin
2 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
3 A Prospective Randomized Study Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Administration in Patients at Risk for Severe OHSS Unknown status NCT01347268 Phase 4
4 A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
5 A Prospective Randomized Study Comparing the Use of hCG or GnRH Agonist to Trigger Final Oocyte Maturation in High Responders Undergoing in-Vitro Fertilization Treatment Completed NCT00349258 Phase 4 Leuprolide acetate
6 Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
7 The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment Completed NCT02670304 Phase 4 letrozole;Aspirin
8 Coasting Versus Gonadotrophin-Releasing Hormone Antagonist Administration in Patients at High Risk of Ovarian Hyperstimulation Syndrome and Its Impact on the Embryos Quality and the Outcome of ICSI Completed NCT03996434 Phase 4 Gonadotropin;Antagonist
9 Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
10 A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl) Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
11 Synchronization of Follicle Wave Emergence and Ovarian Stimulation in Women With a History of Poor Ovarian Response to Treatment Completed NCT00439829 Phase 4 Gonal F;Luveris;Cetrotide;hCG
12 Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
13 Double vs. Single Stimulation in Young Poor Prognosis Patients Followed by a Fresh Embryo Transfer. A Randomized Clinical Trial Recruiting NCT04446845 Phase 4 Double Stimulation (Elonva+rFSH) in luteal /follicular phase;Conventional Stimulation (Elonva+rFSH) in follicular phase
14 Luteal Phase Support Using Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone Supplementation in High Responders Following GnRHa Triggering - A Prospective Randomized Controlled Trial Recruiting NCT04797338 Phase 4 Synarel, 0.2 Mg/Inh Nasal Spray;Estrofem;Utrogestan;Hydroxyprogesterone Caproate
15 An Uncontrolled, Open-label Feasibility Study to Demonstrate That a GnRH Agonist (Decapeptyl) Can be Safely Administered to Trigger Final Oocyte Maturation in High Responder Patients to Mitigate the Risk of OHSS Terminated NCT01714648 Phase 4 Triptorelin 0.2 mg
16 A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG) Terminated NCT01606709 Phase 4 GnRH agonist;hCG
17 Clinical Study of Recombinant Human Follitropin for Injection Assisted in Controlled Ovarian Hyperstimulation Assisted IVF-ET Unknown status NCT03071172 Phase 3 Triptorelin for Injection;Recombinant Human Choriogonadotropin alfa Solution for Injection;Progesterone Soft Capsules
18 The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection . Unknown status NCT02620605 Phase 3 Late Cabergoline 0.5mg;Early Cabergoline 0.5mg
19 The Randomized Clinical Trials of Letrozole Administration During Luteal Phase in Patients Who Have the Risk of Ovarian Hyperstimulation Syndrome Unknown status NCT02686151 Phase 3 Letrozole;Polygeline;Sodium Chloride;dexamethasone
20 Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome Unknown status NCT02823080 Phase 2, Phase 3 Cetrorelix
21 Effect of Cabergoline on Subendometrial Vascularity During ICSI Cycles and Pregnancy Outcome Unknown status NCT02306564 Phase 2, Phase 3 Cabergoline
22 A Phase III, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as Reference Completed NCT00696800 Phase 3 Corifollitropin alfa;Placebo Corifollitropin alfa;Placebo RecFSH / follitropin beta;Ganirelix
23 Does Intravenous Calcium Infusion Effectively Prevent OHSS : a Randomised Controlled Trial Completed NCT01427335 Phase 3 calcium;0.9 % saline
24 A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS. Completed NCT01535859 Phase 3 Cabergoline;Placebo
25 Use of Long Acting GnRH Antagonist to Prevent Ovarian HyperStimulation Syndrome (OHSS) in PCOS Women Undergoing COH for IVF Completed NCT01709942 Phase 3 degarelix (long acting GnRH antagonist);cetrorelix 0.25mg
26 Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction. Completed NCT00440258 Phase 3 Cabergoline
27 Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome Completed NCT01268761 Phase 3 GnRH antagonist (Cetrorelix);Placebo (saline solution)
28 Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02290002 Phase 2, Phase 3 Calcium Dobesilate
29 Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02271360 Phase 2, Phase 3 Calcium Dobesilate;Cabergoline
30 Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome Completed NCT03446625 Phase 3 Resveratrol;Placebo
31 Comparison of Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention:Randomized Controlled Trial Completed NCT03473613 Phase 3 Oral Cabergoline;Calcium Gluconate
32 Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02134249 Phase 2, Phase 3 Diosmin;Cabergoline
33 Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve Completed NCT02150330 Phase 3 Dehydroepiandrosterone (DHEAS)
34 Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: a Randomized Controlled Trial Unknown status NCT02461875 Phase 2 Cabergoline;GnRH antagonist rescue & cabergoline
35 Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome -- A Prospective, Randomized, Controlled Clinical Trial Unknown status NCT02846493 Phase 2 bromocriptine;dexamethasone
36 Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients Undergoing Ovarian Stimulation for IVF With GnRH Antagonists and Recombinant FSH. Unknown status NCT01973842 Phase 2 0.1 mg triptorelin;0.2 mg triptorelin;0.4 mg triptorelin
37 Pathophysiology and Nature of Ovarian Hyperstimulation Syndrome (OHSS) as a Clinical Entity Could be Fully Explained and Effectively Managed as a State of Defective Mineralocorticoid Response Completed NCT04351126 Phase 2 Fludrocortisone 0.1 Milligrams (mg);Bromocriptine
38 Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome. A Randomized Controlled Trial Completed NCT02875587 Phase 2 Cabergoline;Calcium gluconate
39 A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation. Completed NCT00329693 Phase 2 Norprolac;Norprolac;Norprolac;Norprolac
40 Compare the Efficacy of Human Albumin With Cabergoline to Prevent of Ovarian Hyper Stimulation in ART Program Completed NCT01009567 Phase 1, Phase 2 Cabergoline;Control
41 Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome in In-vitro Fertilization Cycles: A Randomized Controlled Trial Completed NCT01014104 Phase 1, Phase 2 Methylprednisolone;Control
42 A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome Completed NCT00665041 Phase 2 Quinagolide
43 Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome - a Randomized Controlled Trial Completed NCT02784457 Phase 2 Cetrorelix
44 Montelukast for Prevention & Treatment of Ovarian Hyperstimulation Syndrome in Freeze-all Cycles Recruiting NCT03794037 Phase 2 dydrgesterone 10 mg( tab)/12hs/14 days
45 Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF) Withdrawn NCT01109888 Phase 1, Phase 2 Cetrotide
46 Luteal Phase Support With Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRh) Agonist in IVF Patients Who Are Risk for Developing OHSS Unknown status NCT02827656 Decapeptyl;hCG luteal support
47 GnRH Antagonist in the Luteal Phase Compared to Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) in Whom All Embryos Are Cryopreserved Unknown status NCT02392520 cetrorelix (cetrotide);Placebo
48 Serum Levels of IMA, TAC, TOS, OSI and MDA in Severe OHSS Patients Underwent Long Agonist Protocol Intracytoplasmic Sperm for Determining Oxidative Stress Status Unknown status NCT02202278
49 Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol Unknown status NCT02022228 triptorelin;hCG;hCG
50 Repeated Injection of GnRH Agonist for Triggering Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol Unknown status NCT02022241 triptorelin

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ganirelix
Ganirelix acetate

Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Genetic Tests for Ovarian Hyperstimulation Syndrome

Genetic tests related to Ovarian Hyperstimulation Syndrome:

# Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 29 FSHR

Anatomical Context for Ovarian Hyperstimulation Syndrome

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

40
Ovary, Endothelial, Pituitary, Liver, Kidney, Breast, Thyroid

Publications for Ovarian Hyperstimulation Syndrome

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 3141)
# Title Authors PMID Year
1
Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. 6 57 54 61
17721928 2008
2
Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. 54 61 57 6
12930928 2003
3
Spontaneous ovarian hyperstimulation syndrome in four consecutive pregnancies. 6 57 61
8894317 1996
4
Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. 54 6 61
16278261 2006
5
A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. 61 6 54
15080154 2004
6
A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. 54 57 61
12930927 2003
7
Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. 54 61 6
9402264 1997
8
Spontaneous ovarian hyperstimulation syndrome presenting with acute abdomen. 61 57
16679690 2006
9
The pathogenesis of the ovarian hyperstimulation syndrome. 57 61
12930924 2003
10
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. 57 61
12498425 2002
11
Follicle-stimulating-hormone receptor and twinning. 6
11213123 2001
12
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. 54 61
20423279 2010
13
Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. 54 61
19800620 2010
14
Ovarian hyperstimulation syndrome (OHSS) due to mutations in the follicle-stimulating hormone receptor. 54 61
20362966 2010
15
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. 54 61
20139430 2010
16
Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. 54 61
19342033 2010
17
Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. 61 54
20008399 2010
18
[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. 54 61
20209851 2009
19
GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. 61 54
19909588 2009
20
GnRHa to trigger final oocyte maturation: a time to reconsider. 61 54
19608565 2009
21
A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats. 54 61
19443574 2009
22
Insights into angiogenic imbalances during pregnancy. 61 54
19622952 2009
23
Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? 61 54
19573290 2009
24
Miscarriage and clinical correlates of leukocyte count in patients with ovarian hyperstimulation syndrome. 61 54
19835500 2009
25
[Analysis of the clinical outcomes of IVF-ET treatment in infertile patients with polycystic ovary syndrome or polycystic ovaries]. 61 54
19460721 2009
26
GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. 54 61
18692821 2009
27
Possible familial gestational spontaneous ovarian hyperstimulation syndrome due to mutation of FSH receptors (FGSOHS). 61 54
19391457 2009
28
Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. 61 54
19088107 2009
29
Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. 61 54
18321487 2009
30
In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols. 54 61
18321490 2009
31
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. 61 54
18367175 2009
32
Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. 61 54
19192339 2009
33
High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. 54 61
19688946 2009
34
Human corpus luteum physiology and the luteal-phase dysfunction associated with ovarian stimulation. 61 54
19406027 2009
35
Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. 54 61
19146764 2009
36
The luteal phase after 3 decades of IVF: what do we know? 54 61
20034417 2009
37
Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. 54 61
18439601 2008
38
Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. 54 61
19102964 2008
39
Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. 61 54
19017414 2008
40
Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? 61 54
18166181 2008
41
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. 61 54
18385260 2008
42
Role of human albumin in ovarian hyperstimulation syndrome. 61 54
18468600 2008
43
Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. 61 54
18171700 2008
44
Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. 54 61
18400585 2008
45
Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. 54 61
18230195 2008
46
Spontaneous ovarian hyperstimulation in a naturally conceived pregnancy with uncontrolled hypothyroidism. 54 61
18238999 2008
47
Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)? 54 61
18164141 2008
48
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. 54 61
18159088 2008
49
The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. 54 61
17462639 2008
50
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. 61 54
17921134 2007

Variations for Ovarian Hyperstimulation Syndrome

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6 (show top 50) (show all 59)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FSHR NM_000145.3(FSHR):c.1346C>T (p.Thr449Ile) SNV Pathogenic 16249 rs28928870 GRCh37: 2:49190614-49190614
GRCh38: 2:48963475-48963475
2 FSHR NM_000145.3(FSHR):c.1699G>A (p.Asp567Asn) SNV Pathogenic 16250 rs28928871 GRCh37: 2:49190261-49190261
GRCh38: 2:48963122-48963122
3 FSHR NM_000145.3(FSHR):c.1345A>G (p.Thr449Ala) SNV Pathogenic 16252 rs121909663 GRCh37: 2:49190615-49190615
GRCh38: 2:48963476-48963476
4 FSHR NM_000145.3(FSHR):c.1634T>C (p.Ile545Thr) SNV Pathogenic 16253 rs121909664 GRCh37: 2:49190326-49190326
GRCh38: 2:48963187-48963187
5 FSHR NM_000145.3(FSHR):c.383C>A (p.Ser128Tyr) SNV Pathogenic 16254 rs121909665 GRCh37: 2:49217768-49217768
GRCh38: 2:48990629-48990629
6 FSHR NM_000145.3(FSHR):c.-58T>C SNV Uncertain significance 336494 rs886056153 GRCh37: 2:49381614-49381614
GRCh38: 2:49154475-49154475
7 FSHR NM_000145.3(FSHR):c.688A>G (p.Ile230Val) SNV Uncertain significance 336486 rs367711694 GRCh37: 2:49196003-49196003
GRCh38: 2:48968864-48968864
8 FSHR NM_000145.3(FSHR):c.685A>G (p.Arg229Gly) SNV Uncertain significance 336487 rs201122960 GRCh37: 2:49196006-49196006
GRCh38: 2:48968867-48968867
9 FSHR NM_000145.3(FSHR):c.1831C>G (p.Leu611Val) SNV Uncertain significance 336479 rs886056149 GRCh37: 2:49190129-49190129
GRCh38: 2:48962990-48962990
10 FSHR NM_000145.3(FSHR):c.373C>A (p.Leu125Met) SNV Uncertain significance 336491 rs886056151 GRCh37: 2:49244629-49244629
GRCh38: 2:49017490-49017490
11 FSHR NM_000145.3(FSHR):c.1330G>A (p.Ala444Thr) SNV Uncertain significance 336482 rs202162496 GRCh37: 2:49190630-49190630
GRCh38: 2:48963491-48963491
12 FSHR NM_000145.3(FSHR):c.1030G>C (p.Val344Leu) SNV Uncertain significance 336483 rs772756688 GRCh37: 2:49190930-49190930
GRCh38: 2:48963791-48963791
13 FSHR NM_000145.3(FSHR):c.225-11T>C SNV Uncertain significance 336492 rs886056152 GRCh37: 2:49247310-49247310
GRCh38: 2:49020171-49020171
14 FSHR NM_000145.3(FSHR):c.947A>G (p.Glu316Gly) SNV Uncertain significance 336484 rs886056150 GRCh37: 2:49191013-49191013
GRCh38: 2:48963874-48963874
15 FSHR NM_000145.4(FSHR):c.1902C>T (p.Arg634=) SNV Uncertain significance 895792 GRCh37: 2:49190058-49190058
GRCh38: 2:48962919-48962919
16 FSHR NM_000145.4(FSHR):c.926G>T (p.Gly309Val) SNV Uncertain significance 895869 GRCh37: 2:49191034-49191034
GRCh38: 2:48963895-48963895
17 FSHR NM_000145.4(FSHR):c.455A>C (p.Gln152Pro) SNV Uncertain significance 895933 GRCh37: 2:49216185-49216185
GRCh38: 2:48989046-48989046
18 FSHR NM_000145.3(FSHR):c.399G>A (p.Lys133=) SNV Uncertain significance 595880 rs148815172 GRCh37: 2:49217752-49217752
GRCh38: 2:48990613-48990613
19 FSHR NM_000145.4(FSHR):c.351G>A (p.Gln117=) SNV Uncertain significance 895934 GRCh37: 2:49244651-49244651
GRCh38: 2:49017512-49017512
20 FSHR NM_000145.4(FSHR):c.1677C>T (p.Pro559=) SNV Uncertain significance 896078 GRCh37: 2:49190283-49190283
GRCh38: 2:48963144-48963144
21 FSHR NM_000145.4(FSHR):c.1664C>T (p.Thr555Ile) SNV Uncertain significance 896079 GRCh37: 2:49190296-49190296
GRCh38: 2:48963157-48963157
22 FSHR NM_000145.4(FSHR):c.898G>A (p.Glu300Lys) SNV Uncertain significance 896140 GRCh37: 2:49191062-49191062
GRCh38: 2:48963923-48963923
23 FSHR NM_000145.4(FSHR):c.707A>G (p.Tyr236Cys) SNV Uncertain significance 896141 GRCh37: 2:49195984-49195984
GRCh38: 2:48968845-48968845
24 FSHR NM_000145.4(FSHR):c.180C>T (p.Val60=) SNV Uncertain significance 896209 GRCh37: 2:49295402-49295402
GRCh38: 2:49068263-49068263
25 FSHR NM_000145.4(FSHR):c.176G>A (p.Arg59Gln) SNV Uncertain significance 896210 GRCh37: 2:49295406-49295406
GRCh38: 2:49068267-49068267
26 FSHR NM_000145.4(FSHR):c.*574T>C SNV Uncertain significance 897605 GRCh37: 2:49189298-49189298
GRCh38: 2:48962159-48962159
27 FSHR NM_000145.4(FSHR):c.1400G>T (p.Arg467Ile) SNV Uncertain significance 897666 GRCh37: 2:49190560-49190560
GRCh38: 2:48963421-48963421
28 FSHR NM_000145.4(FSHR):c.1173A>G (p.Gln391=) SNV Uncertain significance 897667 GRCh37: 2:49190787-49190787
GRCh38: 2:48963648-48963648
29 FSHR NM_000145.4(FSHR):c.645C>T (p.His215=) SNV Uncertain significance 897743 GRCh37: 2:49210074-49210074
GRCh38: 2:48982935-48982935
30 FSHR NM_000145.4(FSHR):c.636T>C (p.Asp212=) SNV Uncertain significance 897744 GRCh37: 2:49210083-49210083
GRCh38: 2:48982944-48982944
31 FSHR NM_000145.4(FSHR):c.135G>A (p.Pro45=) SNV Uncertain significance 897816 GRCh37: 2:49381422-49381422
GRCh38: 2:49154283-49154283
32 FSHR NM_000145.4(FSHR):c.*173G>A SNV Uncertain significance 898763 GRCh37: 2:49189699-49189699
GRCh38: 2:48962560-48962560
33 FSHR NM_000145.4(FSHR):c.1145T>C (p.Ile382Thr) SNV Uncertain significance 898830 GRCh37: 2:49190815-49190815
GRCh38: 2:48963676-48963676
34 FSHR NM_000145.4(FSHR):c.1094T>C (p.Leu365Pro) SNV Uncertain significance 898831 GRCh37: 2:49190866-49190866
GRCh38: 2:48963727-48963727
35 FSHR NM_000145.3(FSHR):c.1576T>C (p.Leu526=) SNV Uncertain significance 336481 rs138281715 GRCh37: 2:49190384-49190384
GRCh38: 2:48963245-48963245
36 FSHR NM_000145.3(FSHR):c.1596G>A (p.Met532Ile) SNV Uncertain significance 336480 rs757909841 GRCh37: 2:49190364-49190364
GRCh38: 2:48963225-48963225
37 FSHR NM_000145.3(FSHR):c.219G>A (p.Glu73=) SNV Uncertain significance 336493 rs377397067 GRCh37: 2:49295363-49295363
GRCh38: 2:49068224-49068224
38 FSHR NM_000145.4(FSHR):c.956A>G (p.Glu319Gly) SNV Uncertain significance 898833 GRCh37: 2:49191004-49191004
GRCh38: 2:48963865-48963865
39 FSHR NM_000145.4(FSHR):c.510T>G (p.Phe170Leu) SNV Uncertain significance 898895 GRCh37: 2:49216130-49216130
GRCh38: 2:48988991-48988991
40 FSHR NM_000145.4(FSHR):c.496G>T (p.Val166Leu) SNV Uncertain significance 898896 GRCh37: 2:49216144-49216144
GRCh38: 2:48989005-48989005
41 FSHR NM_000145.4(FSHR):c.-96A>C SNV Uncertain significance 898968 GRCh37: 2:49381652-49381652
GRCh38: 2:49154513-49154513
42 FSHR NM_000145.3(FSHR):c.*199A>G SNV Uncertain significance 336477 rs886056148 GRCh37: 2:49189673-49189673
GRCh38: 2:48962534-48962534
43 FSHR NM_000145.3(FSHR):c.479T>C (p.Ile160Thr) SNV Uncertain significance 16244 rs121909659 GRCh37: 2:49216161-49216161
GRCh38: 2:48989022-48989022
44 FSHR NM_000145.3(FSHR):c.*563T>C SNV Likely benign 336474 rs80295823 GRCh37: 2:49189309-49189309
GRCh38: 2:48962170-48962170
45 FSHR NM_000145.3(FSHR):c.603C>T (p.Ser201=) SNV Likely benign 336488 rs75552966 GRCh37: 2:49210116-49210116
GRCh38: 2:48982977-48982977
46 FSHR NM_000145.4(FSHR):c.*321A>T SNV Likely benign 897606 GRCh37: 2:49189551-49189551
GRCh38: 2:48962412-48962412
47 FSHR NM_000145.4(FSHR):c.1572C>G (p.Ser524Arg) SNV Likely benign 757090 rs6167 GRCh37: 2:49190388-49190388
GRCh38: 2:48963249-48963249
48 FSHR NM_000145.3(FSHR):c.*111T>C SNV Likely benign 336478 rs140106399 GRCh37: 2:49189761-49189761
GRCh38: 2:48962622-48962622
49 FSHR NM_000145.3(FSHR):c.*246T>A SNV Likely benign 336476 rs72825259 GRCh37: 2:49189626-49189626
GRCh38: 2:48962487-48962487
50 FSHR NM_000145.3(FSHR):c.24G>T (p.Leu8Phe) SNV Likely benign 255348 rs115030945 GRCh37: 2:49381533-49381533
GRCh38: 2:49154394-49154394

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

72
# Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279 rs121909665
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

Expression for Ovarian Hyperstimulation Syndrome

Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.

Pathways for Ovarian Hyperstimulation Syndrome

Pathways related to Ovarian Hyperstimulation Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

Pathways related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1 12.1 LHCGR FSHR FSHB CGA AMH
2
Show member pathways
11.98 REN INS FSHB CGB5 CGA
3 11.9 LHCGR FSHR FSHB CGA
4 11.78 VEGFA KDR INS IL6 ALB
5
Show member pathways
11.67 VEGFA CGB5 CGA
6
Show member pathways
11.59 CYP19A1 CYP11A1 CGA
7 11.35 VEGFA INS IL6
8 11.31 IL6 CYP19A1 CGA
9
Show member pathways
11.26 VEGFA KDR INS
10 11.09 LHCGR FSHR CYP19A1
11 10.93 LHCGR INS FSHR FSHB CYP19A1 CYP11A1
12 10.89 FSHR FSHB CYP19A1 CGA
13 10.47 LHCGR GNRH1 FSHR FSHB CGA

GO Terms for Ovarian Hyperstimulation Syndrome

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 VEGFA REN INS IL6 GNRH1 FSHB
2 endoplasmic reticulum lumen GO:0005788 9.65 INS IL6 F5 BMP15 ALB
3 platelet alpha granule lumen GO:0031093 9.5 VEGFA F5 ALB
4 extracellular region GO:0005576 9.47 VEGFA SHBG REN KDR INS IL6
5 follicle-stimulating hormone complex GO:0016914 9.16 FSHB CGA

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 VEGFA LHCGR INS IL6 GNRH1 FSHR
2 G protein-coupled receptor signaling pathway GO:0007186 10.1 LHCGR INS GNRH1 FSHR FSHB CGB5
3 negative regulation of apoptotic process GO:0043066 9.99 VEGFA KDR IL6 GNRH1 ALB
4 positive regulation of gene expression GO:0010628 9.98 VEGFA INS IL6 FSHB AMH
5 positive regulation of cell proliferation GO:0008284 9.95 VEGFA KDR INS IL6 FSHB CGA
6 cell-cell signaling GO:0007267 9.88 INS GNRH1 CGB5 AMH
7 positive regulation of cell migration GO:0030335 9.8 VEGFA KDR INS FSHB CGA
8 positive regulation of MAPK cascade GO:0043410 9.76 VEGFA KDR INS IL6
9 cellular protein metabolic process GO:0044267 9.72 INS IL6 F5 BMP15 ALB
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 VEGFA KDR INS FSHR
11 gonad development GO:0008406 9.61 FSHR AMH
12 positive regulation of positive chemotaxis GO:0050927 9.6 VEGFA KDR
13 vascular wound healing GO:0061042 9.57 VEGFA KDR
14 Sertoli cell proliferation GO:0060011 9.55 FSHR FSHB
15 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.54 VEGFA KDR
16 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.52 VEGFA KDR
17 ovulation cycle process GO:0022602 9.51 LHCGR FSHR
18 follicle-stimulating hormone signaling pathway GO:0042699 9.49 FSHR FSHB
19 female gamete generation GO:0007292 9.46 FSHR FSHB CGB5 BMP15
20 positive regulation of steroid biosynthetic process GO:0010893 9.43 FSHB CGA
21 peptide hormone processing GO:0016486 9.43 FSHB CGB5 CGA
22 hormone-mediated signaling pathway GO:0009755 9.35 REN LHCGR FSHR FSHB CGB5
23 ovarian follicle development GO:0001541 9.02 VEGFA LHCGR FSHR FSHB BMP15

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 VEGFA IL6 BMP15 AMH
2 protein-hormone receptor activity GO:0016500 9.26 LHCGR FSHR
3 hormone activity GO:0005179 9.1 INS GNRH1 FSHB CGB5 CGA AMH
4 follicle-stimulating hormone activity GO:0016913 8.96 FSHB CGA

Sources for Ovarian Hyperstimulation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....